Examining the role of inflammation in blood cell deficiencies after CAR-T therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with diffuse large B-cell lymphoma who have undergone CAR-T cell therapy. It aims to analyze the characteristics of the hematopoietic niche and the inflammatory status in patients experiencing prolonged cytopenias compared to those without. The study will involve a series of 40 patients and will utilize techniques such as immunohistochemistry, flow cytometry, and genomic studies to gather data. The goal is to better understand the complications arising from CAR-T therapy and explore potential therapeutic interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with diffuse large B-cell lymphoma undergoing consecutive commercial CAR-T therapy
* Over 18 years old
* Sign the informed consent

Exclusion Criteria:

* Under 18 years old
* Do not sign the informed consent

Where it's running

• Complejo Asistencial Universitario de Salamanca
  Salamanca, Spain Recruiting

Study contacts

• Study coordinator: Fermín Sánchez-Guijo Martín, PhD MD
• Email: ferminsg@usal.es
• Phone: +34 923 291384

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using itacitinib to improve CAR T cell therapy outcomes in lymphoma patients

  This study is testing if taking itacitinib before and after CAR T cell therapy can help improve outcomes for lymphoma patients with high inflammation levels.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT05757219

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Anti‑PD1 armored CD19 CAR‑T therapy for relapsed or refractory diffuse large B‑cell lymphoma

  This trial will test whether anti‑PD1 armored CD19 CAR‑T cell therapy is safe and tolerable in adults with relapsed or refractory diffuse large B‑cell lymphoma.

  Recruiting Phase 1 Jiangsu Topcel-KH Pharmaceutical Co., Ltd. · Suzhou · NCT07368270

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• CD7 CAR T-Cell Therapy for T-Cell Lymphomas

  This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.

  Recruiting at 4 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06925464

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.